These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2087597)

  • 1. A dual dominant selection, dual marker gene amplification model for environmental surveillance of recombinant viral vaccines.
    Katz JB
    Res Virol; 1990; 141(6):591-6. PubMed ID: 2087597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host-related immunomodulators encoded by poxviruses and herpesviruses.
    McFadden G; Murphy PM
    Curr Opin Microbiol; 2000 Aug; 3(4):371-8. PubMed ID: 10972497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poxviruses as vectors for veterinary vaccines.
    Boyle DB
    Aust Vet J; 1989 Dec; 66(12):419-20. PubMed ID: 2695041
    [No Abstract]   [Full Text] [Related]  

  • 4. Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines.
    Taylor J; Paoletti E
    Prog Vet Microbiol Immunol; 1988; 4():197-217. PubMed ID: 3078866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of recombinant fowlpox viruses as vectors for poultry vaccines.
    Boyle DB; Coupar BE
    Virus Res; 1988 Jun; 10(4):343-56. PubMed ID: 2842977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of herpesviridae as recombinant viral vectors in vaccine development against animal pathogens.
    Kamel M; El-Sayed A
    Virus Res; 2019 Sep; 270():197648. PubMed ID: 31279828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of vaccine vectors.
    Dorner F
    Dev Biol Stand; 1995; 84():23-32. PubMed ID: 7796959
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy studies on a canarypox-rabies recombinant virus.
    Taylor J; Trimarchi C; Weinberg R; Languet B; Guillemin F; Desmettre P; Paoletti E
    Vaccine; 1991 Mar; 9(3):190-3. PubMed ID: 2042391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prime-boost strategy: exciting prospects for improved vaccination.
    Ramshaw IA; Ramsay AJ
    Immunol Today; 2000 Apr; 21(4):163-5. PubMed ID: 10740236
    [No Abstract]   [Full Text] [Related]  

  • 10. Protective vaccination of ferrets against canine distemper with recombinant pox virus vaccines expressing the H or F genes of rinderpest virus.
    Jones L; Tenorio E; Gorham J; Yilma T
    Am J Vet Res; 1997 Jun; 58(6):590-3. PubMed ID: 9185963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant viruses as vaccines against viral diseases.
    Souza AP; Haut L; Reyes-Sandoval A; Pinto AR
    Braz J Med Biol Res; 2005 Apr; 38(4):509-22. PubMed ID: 15962176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of thymidine kinase and neomycin phosphotransferase II positive selection systems for recovery of genetically atypical and recombinant DNA vaccine viruses.
    Katz JB; Middle LA
    Biologicals; 1990 Oct; 18(4):301-4. PubMed ID: 2178350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approaches for genetic purity testing of live recombinant viral vaccines using a human adenovirus:rabies model.
    Lutze-Wallace C; Sapp T; Nadin-Davis SA; Wandeler A
    Can J Vet Res; 1992 Oct; 56(4):360-4. PubMed ID: 1477804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New approaches to the development of virus vaccines for veterinary use.
    Yamanouchi K; Barrett T; Kai C
    Rev Sci Tech; 1998 Dec; 17(3):641-53. PubMed ID: 9850535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. gpt-gus fusion gene for selection and marker in recombinant poxviruses.
    Cao JX; Upton C
    Biotechniques; 1997 Feb; 22(2):276-8. PubMed ID: 9043698
    [No Abstract]   [Full Text] [Related]  

  • 16. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC.
    Paoletti E; Taylor J; Meignier B; Meric C; Tartaglia J
    Dev Biol Stand; 1995; 84():159-63. PubMed ID: 7796949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Virokines and viroceptors--viral immunomodulators with clinical and therapeutic implications].
    Kontsek P; Kontsekova E
    Bratisl Lek Listy; 2000; 101(7):371-82. PubMed ID: 11059106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal vaccine vectors: replication-competent versus replication-deficient poxviruses.
    Karkhanis LU; Ross TM
    Curr Pharm Des; 2007; 13(19):2015-23. PubMed ID: 17627535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans.
    Kanesa-thasan N; Smucny JJ; Hoke CH; Marks DH; Konishi E; Kurane I; Tang DB; Vaughn DW; Mason PW; Shope RE
    Vaccine; 2000 Oct; 19(4-5):483-91. PubMed ID: 11027812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccines give written description guidance.
    Nat Rev Drug Discov; 2006 Jul; 5(7):532. PubMed ID: 16883644
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.